Latest headlines
Gilead Sciences News
The latest Gilead Sciences (GILD) news, aggregated as it breaks. News moves sentiment and sentiment moves price, so read these GILD headlines next to the live Gilead Sciences Fear and Greed Index.
Latest Gilead Sciences Headlines48
Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
zacks.com · Jul 30, 2026
Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?
zacks.com · Jul 30, 2026
Gilead: Buy The Distortion Before Q2 Clears It Up
seekingalpha.com · Jul 30, 2026
Gilead to Report Q2 Earnings: How Should You Play the Stock Now?
zacks.com · Jul 29, 2026
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
zacks.com · Jul 28, 2026
Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for
zacks.com · Jul 28, 2026
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
zacks.com · Jul 24, 2026
CHMP Recommends Gilead's Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
businesswire.com · Jul 24, 2026
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise?
zacks.com · Jul 23, 2026
Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB?
fool.com · Jul 23, 2026
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
businesswire.com · Jul 21, 2026
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials
reuters.com · Jul 21, 2026
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
businesswire.com · Jul 21, 2026
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know
zacks.com · Jul 17, 2026
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
zacks.com · Jul 16, 2026
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
reuters.com · Jul 14, 2026
Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.
fool.com · Jul 12, 2026
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
zacks.com · Jul 10, 2026
2 Recession-Resistant Dividend Stocks to Buy and Hold
fool.com · Jul 10, 2026
A Look at Gilead Sciences Inc (GILD) After 5.2% Gain -- GF Value $96.06 vs Price $136.36
gurufocus.com · Jul 7, 2026
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
zacks.com · Jul 6, 2026
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
benzinga.com · Jul 6, 2026
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
zacks.com · Jul 2, 2026
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
zacks.com · Jun 29, 2026
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
zacks.com · Jun 25, 2026
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
zacks.com · Jun 25, 2026
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
businesswire.com · Jun 24, 2026
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
zacks.com · Jun 24, 2026
Gilead Sciences: The Market Is Underestimating Its Growth Runway
seekingalpha.com · Jun 23, 2026
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
businesswire.com · Jun 23, 2026
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
zacks.com · Jun 18, 2026
The Healthcare M&A Wave
forbes.com · Jun 17, 2026
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
zacks.com · Jun 16, 2026
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
zacks.com · Jun 15, 2026
U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
businesswire.com · Jun 15, 2026
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
businesswire.com · Jun 12, 2026
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
zacks.com · Jun 11, 2026
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
businesswire.com · Jun 11, 2026
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
etftrends.com · Jun 11, 2026
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
zacks.com · Jun 10, 2026
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 9, 2026
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
zacks.com · Jun 9, 2026
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
benzinga.com · Jun 9, 2026
Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
businesswire.com · Jun 8, 2026
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
businesswire.com · Jun 8, 2026
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
marketbeat.com · Jun 8, 2026
Baron Discovery Fund Q1 2026: Who Moved The Needle
seekingalpha.com · Jun 8, 2026
Dividend Champion, Contender, And Challenger Highlights: Week Of June 7
seekingalpha.com · Jun 5, 2026
Why Is Gilead Sciences Up or Down Today?
When Gilead Sciences (GILD) moves sharply, the reason is almost always in the headlines above. Earnings, guidance, analyst upgrades and downgrades, product news and macro data are the usual drivers of a GILD move on the day. The feed shows what broke and when, and the sentiment tag on each story shows whether the coverage skews positive or negative, so you can see at a glance why Gilead Sciences is up or down today.
How Gilead Sciences News Affects the Price
News does not move the Gilead Sciences (GILD) price directly, it moves sentiment, and sentiment moves price. A run of negative headlines pulls the Gilead Sciences Fear and Greed Index toward fear, while positive coverage pushes it toward greed, often before the price has fully reacted. A surprise story usually shows up first as a spike in Gilead Sciences trading volume. That is the chain to watch: headline, sentiment, volume, then the GILD price.
Trade the Gilead Sciences News With Sentiment
Headlines tell you what happened; the Fear and Greed Index tells you how the crowd is reacting. Watch Gilead Sciences trading volume spike on a big story, check the Gilead Sciences price history for context, follow the live GILD price, see the Gilead Sciences price prediction, and read the Gilead Sciences Fear and Greed Index for mood.
How do you feel about Gilead Sciences?
1DFrequently asked questions
Why is Gilead Sciences up or down today?
What is the latest Gilead Sciences news?
Where does Gilead Sciences news come from?
How often is Gilead Sciences news updated?
How does Gilead Sciences news relate to its Fear and Greed Index?
Headlines are aggregated from third-party sources and link to the original publishers. CFGI does not author or endorse them.
About CFGI
The per-asset sentiment record.
CFGI is a market sentiment data company that scores crowd emotion from 0 to 100 across crypto and stock markets. Crypto readings cover the whole market and hundreds of individual assets across 15-minute, 1-hour, 4-hour and daily views. The stock index gives a live daily reading for wider stock market sentiment.
Every CFGI score is built from 10 indicators: price, volatility, volume, impulse, technical analysis, social media, dominance, search interest, whale movements and order book pressure. The same data powers our API, alerts and embeddable widgets.